For laboratories
multi-gene ctDNA panel. Lab participation agreement. Pharma sponsor channel.
Regional biopsy labs with existing NGS infrastructure run the panel under their existing CLIA number. The gene-to-therapy matrix, bioinformatics pipeline, and pharma sponsor channel are delivered by Atumnus. No new physician acquisition. No new capex.
Lab partnership application
Revenue model
Panel revenue and pharma sponsor channel — three volume scenarios.
| Scenario | Volume | Gross panel revenue | Lab participation share | + Sponsor channel |
|---|---|---|---|---|
| Conservative | 25 practices × 30 tests/year | $2.63M | $1.84M | +$0.45M |
| Base case | 50 practices × 30 tests/year | $5.25M | $3.67M | +$0.90M |
| Full network | 100 practices × 30 tests/year | $10.50M | $7.35M | +$1.80M |
| Pharma sponsor channel | Registered studies × ~100 patients | Outside Medicare billing | See agreement | 100% to lab |
How the partnership works
Specimen to enrolled patient — three steps.
01
Lab processes the specimen
Blood draw ordered by urologist. Lab runs multi-gene ctDNA panel on existing NGS infrastructure under existing CLIA number. No new equipment. No new certification.
02
Atumnus delivers the framework
Clinical ordering framework, gene-to-therapy matrix, and VerifiedEnroll integration. Atumnus provides the bioinformatics pipeline. Lab provides the assay.
03
Sponsor-funded companion diagnostic channel
Companion diagnostic testing channel activates for matched Atumnus-registered studies. Sponsor-direct compensation outside Medicare billing. Lab participation agreement governs payment structure.
Panel specifications
multi-gene ctDNA panel.
Genes
104
Indications
Prostate · Bladder · RCC
Sensitivity
low VAF
Sample type
Blood draw only
Billing
Standard NGS CPT codes
Certification
Existing CLIA
FAQ
Lab partnership questions.
Does Medicare cover the panel?
The pharma sponsor channel operates outside Medicare billing. The panel may be billed through standard NGS CPT codes depending on clinical indication. Atumnus provides a billing framework as part of the partnership.
What is the lab participation agreement?
Revenue participation terms are established in the signed lab participation agreement. Companion diagnostic compensation is governed by a separate sponsor agreement instrument. Terms provided upon application.
What CLIA requirements apply?
Labs must hold existing CLIA certification for NGS-based oncology testing. No new certification required. The lab runs the assay under its existing CLIA number.
What is the timeline to first panel revenue?
60–90 days from signed partnership agreement to first panel revenue. Bioinformatics integration, ordering framework deployment, and physician communication infrastructure. Pharma sponsor channel activation runs in parallel.
Apply
Lab partnership application
Applications reviewed within 5 business days. Labs with existing NGS oncology certification are reviewed first.